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Abstract
Background: The introduction of genomics and biobanking methodologies to the African research context has
also introduced novel ways of doing science, based on values of sharing and reuse of data and samples. This shift
raises ethical challenges that need to be considered when research is reviewed by ethics committees, relating for
instance to broad consent, the feedback of individual genetic findings, and regulation of secondary sample access
and use. Yet existing ethics guidelines and regulations in Africa do not successfully regulate research based on
sharing, causing confusion about what is allowed, where and when.
Methods: In order to understand better the ethics regulatory landscape around genomic research and biobanking,
we conducted a comprehensive analysis of existing ethics guidelines, policies and other similar sources. We sourced
30 ethics regulatory documents from 22 African countries. We used software that assists with qualitative data
analysis to conduct a thematic analysis of these documents.
Results: Surprisingly considering how contentious broad consent is in Africa, we found that most countries allow
the use of this consent model, with its use banned in only three of the countries we investigated. In a likely
response to fears about exploitation, the export of samples outside of the continent is strictly regulated, sometimes
in conjunction with regulations around international collaboration. We also found that whilst an essential and
critical component of ensuring ethical best practice in genomics research relates to the governance framework that
accompanies sample and data sharing, this was most sparingly covered in the guidelines.
Conclusions: There is a need for ethics guidelines in African countries to be adapted to the changing science
policy landscape, which increasingly supports principles of openness, storage, sharing and secondary use. Current
guidelines are not pertinent to the ethical challenges that such a new orientation raises, and therefore fail to
provide accurate guidance to ethics committees and researchers.
Background
The introduction of genomics and biobanking method-
ologies to the African research context through plat-
forms such as MalariaGEN [1], 1000Genomes [2] and
H3Africa [3] has simultaneously introduced some of the
ethical challenges associated with it [4, 5]. Underlying
such research is a shift in the way in which research is
conducted, towards greater openness, sharing of re-
sources, collaboration between scientists from across the
world, and re-use of samples and data for secondary re-
search. This shift has introduced a requirement to re-
consider some of the key ethical principles and practices
of health research. Most notably, narrow conceptualiza-
tions of informed consent as constituting an agreement
to participate in one research project with a clearly de-
fined question are not tenable in such research and are
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gradually being substituted with an acceptance that
broad consent—or at least tiered consent—areethically
acceptable and more appropriate consent models to be
used in such research [6, 7]. Related to this shift is
greater focus on considering the governance of scientific
resources, for instance through data sharing policies that
promote ethical best practice [8].
Yet these changes are often not incorporated in the
regulatory documents that guide researchers and ethics
committees. In assisting H3Africa researchers [3] navi-
gate the landscape of ethical regulations, guidelines and
ethics review across the continent, it became clear that
African regulation is either absent, outdated, conserva-
tive or difficult to navigate. Simultaneously, the ethics
committees that apply these regulations tend to be very
cautious about approving genomics and biobanking
study proposals, particularly where these involve pro-
posals to use a broad consent model or to share samples
for unspecified future use with researchers from across
the globe. Such a wary approach is not surprising given
the history of biomedical interventions across the con-
tinent [9–11], which has led to a mistrust of inter-
national collaborations and a perceived need to protect
local scientists and populations from outside research
agendas. Most pertinently, such past experiences offered
little opportunity for African scientists to intellectually
engage in, or lead, African health research, and often re-
duced their contribution to operational tasks such as for
instance those relating to sample collection [12]. These
past practices inform current legislation, policies and
tentative responses to unknowns involved in genomic re-
search [13]. In response to these challenges, we set out
to not only work with members of ethics committees
and National Ethics Councils to explore ethical chal-
lenges around genomic research and biobanking [14,
15], but we also put together a comprehensive analysis
of the existing ethics regulatory framework for genomics
and biobanking research, which we report in this paper.
In our review, we built on other similar although more
restricted reviews published in the literature. A 2013
study [16] reviewed international and African guidelines,
policies and standard procedures for genomic research
across 11 African countries to document how they ad-
dress issues of confidentiality, import/export of samples,
secondary use of samples and informed consent. In
2012, Sather and Dhai documented how guidelines in 6
African countries (5 of which overlapped with Staunton
and Moodley [16]) compare to those of higher income
countries and countries in the BRICS zone [17]. Argu-
ably the most comprehensive analysis of national regula-
tory guidelines was performed by [18] who documented
how regulation in three African countries (also covered
in the other sources) addressed consent to and
authorization for export of human biological material
collected as part of research. All three studies showed
that the guidelines differed considerably and Staunton
and Moodley concluded that this could negatively affect
collaboration in genomic research. Santhar and Dhai re-
ported that most African countries as well as countries
in the BRICS region preferred specific consent unlike
other developed countries. These three studies collect-
ively reviewed documents from 12 African countries. Re-
cent publications detailed the regulation of genomics
and biobanks in Zambia [19], South Africa [20] and
Nigeria [21], which we included in our analysis.
In this paper, we report the results of a review that
had the aim to document whether and how African
country guidelines and policy documents discuss gen-
omic research and biobanking research, and we specific-
ally explored provisions for the use of broad consent to
support such research. The analysis of the review fo-
cused on permitted informed consent types, guidance on
the reuse of samples collected as part of research, sam-
ple storage, ownership of samples collected as part of re-
search and the export of samples collected as part of
research.
Method
We sourced ethics documentation from the countries in-
volved in H3Africa research through personal contacts,
bioethics databases and Google. We first searched all the
online ethics documents databases or repositories
known to us. We searched the UNESCO Global Ethics
Observatory (GEObs) [22], the Health Research Web
(HRWeb) [23], the 2015 edition of the International
Compilation of Human Subjects Standards compiled by
the US Office of Human Research Protections, [24] the
Training And Resources In Research Ethics Evaluation
(TRREE) database, [25] and the ClinRegs database [26].
To cast our net as wide as possible, we also googled eth-
ics guidelines and regulations on human subjects’ pro-
tections, genetic/genomic research and biobanking
research in Africa. Where we felt there was a gap in our
information, we googled the country name together with
selected keywords, for instance ‘Namibia, export, bio-
logical samples’. In this way, we identified a few add-
itional sources including a recent Kenyan ethics
guideline dealing with sample export and storage. Whilst
there is an important difference between laws and other
regulatory ethics documents (in the sense that the first
are mandatory, the second may not be), we were inter-
ested primarily in ethical guidance for health research.
For this reason, in our search we primarily focused on
the identification of regulatory ethics documents (guide-
lines, SOPs and so forth). In countries that did not have
ethics guidelines but that had laws prescribing good eth-
ical practice—such as is the case in Zambia, Senegal and
Benin for instance—we included such laws in our study.
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Finally, we contacted H3Africa researchers and mem-
bers of research ethics in 21 African countries and re-
quested copies of any guidelines we did not yet have.
Specifically, we targeted researchers and members of
ethics committees attending the H3Africa Ethics Con-
sultation meetings [14], at which ethics committees from
over 20 African countries were present. During the sec-
ond H3Africa Consultation Meeting, which was held in
Zambia in May 2015 [15], we circulated lists of all the
documents we had sourced for each country and asked
meeting attendants to check for completeness. In this
way, we sourced an additional few documents that we
had not obtained through our other search strategies, in-
cluding national ethical guidelines from Ghana which
are still in their draft form.
All guidelines were imported into NVivo 10 [27] for
thematic analysis using a pre-defined coding scheme.
The coding scheme covered themes on consent, owner-
ship of samples, destruction of samples, international
guidelines, sample and data sharing. The coding scheme
was discussed by members of the H3Africa working
group on ethics and documents in NVivo were coded by
two researchers (JDV, NSM). Because not all researchers
had access to NVivo, we exported the coding scheme
into Excel and asked the contributing authors to
summarize pertinent aspects of the guidelines they
were analysing in the Excel spreadsheet, and to
summarize the guidelines’ position on issues pertinent
to genomics and biobanking research. Where we were
unsure about the interpretation of the guidelines, we
sought advice from our contacts in the countries con-
cerned. This was particularly pertinent in the case of
Ethiopia, where there is ongoing ambiguity about the
applicability of biodiversity legislation on human gen-
etic research.
Results
We collected a total of 30 documents from 22 African
countries (see Table 1 for an overview). The type of doc-
uments—and thus the sources of ethics guidance—var-
ied tremendously across countries. They included:
standard operating procedures; national guidelines for
health research; national guidelines for genetic research;
ministerial decrees and laws. Most of the documents
were published in the last 5 years. The oldest was pub-
lished in 1997 in Guinée, while the latest was published
in 2015 in South Africa. The Ethiopian guidelines were
revised in 2014 primarily to include aspects of genetic
and collaborative research—we only reviewed the sec-
ond edition of those guidelines. The documents we
reviewed were published by different authorities, in-
cluding Ministries of Health, National Ethics Commit-
tees, National Councils for Science and Technology,
Parliament and an Office of the President. Where
countries had ethics regulations or guidelines interpreting
the legal framework, we only examined those without
also examining the laws impacting on health research.
In the following, we detail those instances in which
country regulations do address particular topics. If
countries are not mentioned under the different
topics discussed in the remainder of the paper, then
this is because they are silent on those topics.
Nature of documents
Of the countries we included in our analysis, only
(Malawi, Nigeria and South Africa) had specific na-
tional or local guidelines for genomic and/or biobank-
ing research. Malawi and Nigeria both had national
guidelines published as addendums to the National
Health Research Ethics Guidelines. The Malawian ad-
dendum focuses on human genetic research, whilst
the Nigerian addendum focuses on storage of human
samples in biobanks. In South Africa one of the uni-
versity ethics committees had developed a local guide-
line for biobanking research, which we included in
our analysis.
Of the countries we included in our analysis, only
Benin and Senegal seem to have regulated health re-
search through specific Health Research Ethics laws.
Zambia has a Health Research Act which also contains
large sections relating to research ethics, whilst in most
other countries health research and research ethics are
regulated through different laws for instance those per-
taining to health and healthcare. In a number of coun-
tries, for instance in South Africa and Nigeria, the
Health Acts devolve responsibility for development of
ethics guidelines to national research ethics councils.
Only the Zambian Health Research Act published in
2013 specifically mentions and regulates genomics and
biobanking research. In the other countries, insofar as
we are able to assess, genomics and biobanking are not
specifically mentioned or addressed in the legal
framework.
In all the other countries, provisions for genomics and
biobanking were incorporated in the main national eth-
ics guidelines, either deserving separate description or
exceptional status (such as in Rwanda, Ethiopia and draft
guidelines for Ghana), or by implication (such as
Cameroon) because the guidelines discuss topics pertin-
ent to genomics and biobanking, such as sample sharing
or broad consent.
Consent for genomic research
There appears to be increasing international acceptance
for broad consent to be the ‘best compromise’ consent
model to promote the sharing of scientific resources,
balancing patient preferences, participant protection,
and the utility of data and samples that are collected
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[28]. Specifically for genomics and biobanking research,
some work has gone into exploring whether and when
the use of broad consent is ethical, both internationally
[6] and in Africa specifically [7]. Being the pillar of ethics
regulation of health research worldwide, it is hardly sur-
prising that informed consent was discussed in all the
documents we reviewed. There is, however, tremen-
dous difference in the way in which informed consent
is described—from being more abstract and aspir-
ational as in the case of the guidelines from Kenya,
to being very detailed and descriptive as in the case
of guidelines from Malawi.
Table 1 List of countries and documents included in the analysis
Country Nature document Title of document Year of
Publication
Benin Law Code D’ Éthique et de Déontologie pour La Recherche en Santé en République du Bénin. 2010
Botswana National guidelines Standard Operating Procedures for Review Of Biomedical and Bio-Behavioural Research in
Botswana
2011
Cameroon SOP Standard Operating Procedures for Research Ethics Committees (RECs) in Cameroon 2012
Ethiopia National guidelines National Research Ethics Review Guideline Fifth Edition 2014
Ghana National Guidelines Draft National Ethics Guidelines and Standard Operating procedures of Institutional Review
Boards
In
Development
Guinea SOP Procédure Opératoire Standardisée d’Examen d’un Projet de Recherche Biomédicale 2013
Livre Troisieme de l’Éthique pour la Recherche en Santé 1997
Kenya National guidelines Guidelines for Ethical Conduct of Biomedical Research Involving Human Subjects in Kenya 2004
Lesotho SOP Standard Operating Procedures for the National Health Research Ethics Committee 2013
Malawi National Guidelines for
genetic research
Policy Requirements, Procedures and Guidelines for the Conduct and Review of Human
Genetic Research in Malawi
2012
Mauritius Law The Clinical Trials Bill 2010
National guidelines Ethical Guidelines for Biomedical Research Involving Human Subjects 2003
Namibia National guidelines Guidelines on Clinical Trials in human subjects 2003
Research Management Policy 2003
Nigeria National guidelines National Code of Health Research Ethics 2007
Policy Statement on Storage of Human Samples in Biobanks and Biorepositories in Nigeria 2013
Rwanda SOP National ethics Committee Standard Operating Procedures 2009
Senegal Law Code d’Éthique pour la Recherche en Santé 2009
Ministerial decree Arrêté Portant Adoption des Bonnes Pratiques Cliniques (BPC ICR) pour la Conduite des Essais
Cliniques.
2011
Arrêté Ministeriel Portant Adoption du Guide du Chercheur et de la Brochures des Membres
du CNERS pour l’Évaluation et le Suivi des Protocols de Recherche
2013
Sierra
Leone
National guidelines Guidelines for conducting clinical trials of medicines, food supplements, vaccines, and medical
devices in sierra Leone.
Not Stated
Guideline For Good Clinical Practice (GCP) In Sierra Leone
South
Africa
Law National Health Act 2003
National guidelines Department of Health Guidelines, 2nd edition 2015
MRC guidelines on Ethics for medical research, reproductive biology and genetic research 2002
Sudan National guidelines National Guidelines for Ethical
Conduct of Research Involving Human
Subjects
2008
Tanzania National Ethics
Guidelines
Guidelines of Ethics for Health
Research in Tanzania
2009
Togo Ministerial Decree Charte du Comité de Bioéthique pour la Recherche en Santé 2009
Uganda National Guidelines National Guidelines for Research Involving Humans as Research Participants 2014
Zambia Law The National Health Research Act 2013
Zimbabwe National guidelines Ethics Guidelines for Health Research Involving Human Participants in Zimbabwe 2011
SOP Standard Operating Procedure
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The use of broad consent for future unspecified uses
is specifically prohibited only in Zambia, where the 2013
Health Research Act stipulates that “A person shall not
withdraw blood, blood products, tissue or gametes from
a living person for any unspecified future health research
activity or unspecified storage” (Zambia Health Research
Act, provision 47(2))—a provision that is currently ap-
plied by Zambia’s National Health Research Ethics
Council (James Munthali, personal communication).
The potential effect of this provision to effectively block
health research in the country led some Zambian au-
thors to call for a revision of the Health Act [19]. If sam-
ples need to be stored for research that is in line with
the original research for which samples were collected,
then Zambian researchers are required to use a separate
consent form. Although the use of broad consent is not
specifically discussed or prohibited in Malawi and
Tanzania, the guidelines for these two countries also
suggest that it may not be used. In Malawi, the collec-
tion of samples for unspecified future use is not allo-
wed—which suggests that the use of broad consent
would also not be permissible. In Tanzania, the 2009
Guidelines for Health Research forward the position that
“consent is provided for the intended study, and it is un-
ethical to use specimens for purposes other than those
consented for” (pg 86, section 8.8). Where researchers
want to use stored samples for secondary research, the
Tanzanian guidelines require that researchers submit a
new protocol for ethics review. Although the document
does not describe whether participants ought to be
recontacted for consent, but that seems to be the intent
of the 2010 Material Transfer Agreement (MTA). The
2010 Tanzanian MTA form notes that those involved
“shall use all reasonable efforts to maintain the consents
in effect once obtained” (pg 6, article VI.a).
In the majority of countries (Benin, Ghana, Guinee,
Kenya, Lesotho, Mauritius, Namibia, Swaziland, Togo
and Zimbabwe), the description of consent requirements
is generic, and broad consent is neither prevented nor
promoted. The absence of specific stipulations in the
guidelines for these countries suggests that broad con-
sent could possibly be used. In Kenya, the national
guidelines stipulate that if the identity of the sample
donor is known, then they should be re-consented for
future use or the ethics committee must provide a wai-
ver of this requirement. This latter requirement was
strengthened in more recent (2014) guidelines for the
export and storage of human biological samples, in
which it is stipulated that sample donors should prefera-
bly consent to sample export (and, presumably, storage)
but if for some reason they have not, then researchers
should seek a waiver from the ethics committee.
In the guidelines from the remainder of the countries
(Botswana, Sierra Leone, Senegal, Uganda, Cameroon,
Nigeria, South Africa, Sudan, Rwanda, Nigeria and
Ethiopia), consent for future unspecified research is
mentioned and allowed, but with conditions attached.
Guidelines from Botswana, Sierra Leone, Senegal and
Uganda require that a separate form be used to seek
consent for any future use—which looks like a regulatory
preference for tiered consent. Guidelines for Cameroon,
Nigeria, South Africa and Sudan do not require separate
consent forms for future use, but rather stipulate that
participants need to be informed of intentions to store
samples for future research. A caveat in Sudan is that
the regulations require that participants are re-
consented at ‘regular intervals’, without specifying what a
reasonable timeline for re-consenting would be. This
provision is not specific to genomic research and bio-
banking however; participants in ongoing epidemio-
logical research also need to be re-consented at regular
intervals, even when the study aims remain the same. Fi-
nally, the guidelines for Rwanda, Nigeria and Ethiopia
specify that broad consent can be used for the collection
of samples for future use, but leave it up to ethics com-
mittees to decide on the appropriateness of the consent
models proposed in research. Nigeria is the only country
that specifically mentions and allows ‘broad consent’,
which is defined as “consent in which the type or pur-
pose of research is defined in broad terms and for a
work that is not specified by time” (Section E.2 of the
Policy Statement). On the contrary, blanket consent,
which is defined as consent “in which the type or pur-
pose of the research is not defined in any way and does
not restrict the use of donated specimen to any type of
research” (ibid) is not allowed.
Storage of samples
Whilst sample storage is allowed in all countries (expli-
citly or implicitly), only few countries offer specific guid-
ance on the timeframe for storage. In Zambia, samples
can only be stored for a period not exceeding 10 years
and permission is required for storage longer than
10 years. Samples can only be stored in designated re-
search facilities. In Malawi, samples cannot be stored for
more than 5 years. Research specifically aimed at storing
human biological materials for future research or retro-
spective genetic analysis is not allowed in Malawi.
Guidelines from Zimbabwe describe that extraterritorial
storage of samples beyond the study period is not
allowed. It is not clear how the national regulator en-
sures compliance with this provision.
Re-use of samples
In the documents we reviewed, those from 14 countries
specifically address issues of re-use of samples collected
as part of research. In Botswana, Ghana, Ethiopia,
Rwanda, Uganda, Kenya, Nigeria, Senegal, Sudan and
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Tanzania re-use of samples requires approval from an
ethics committee. The other countries are silent on
whether ethics approval is required for re-use. In
Botswana, the formal requirement is for sample donors
to be re-consented before their samples are used again;
however this requirement can be waived by an ethics
committee. In Ethiopia, the sharing of samples without
consent, ethics approval and an MTA is mentioned as a
specific example of research misconduct. In Rwanda the
re-use of samples is subject to approval by the National
Health Research Ethics Committee. In Malawi, sample
collection for future use is not allowed, which suggests
that re-use of samples is also not allowed. In Uganda,
decisions on the re-use of samples collected as part of
research will be determined by the institution that has
custodianship of the samples. Although provisions for
the re-use of samples are mentioned in the Zambian
Health Research Act 2013, these do not describe who
can access stored samples, for what purposes, and
whether secondary use requires ethics approval.
Export of samples and international collaboration
In contrast to provisions around sample storage and re-
use, the export of samples is rather tightly controlled in
many African countries. The guidelines from ten coun-
tries offer explicit guidance for the export of samples,
and in all of these countries researchers require approval
or permission from one or more national agencies, for
instance from a national ethics review body (Ethiopia,
Lesotho, Nigeria and Rwanda); from a national regula-
tory authority (Botswana, Malawi, South Africa and
Zambia); from a Ministry of Health (Cameroon and
Zambia); or from a national body for health research,
medical research or for science and technology more
broadly (Kenya, Uganda and Zimbabwe).
National-level approval is usually required in addition
to (or as part of ) ethics approval for the primary collec-
tion of the samples. In some cases, this national approval
or permission takes the form of export permits only
(such as is the case in South Africa, see [20]). In other
countries (such as Ethiopia and Zimbabwe), researchers
need to obtain both national-level ethics approval and
an export permit.
Some countries (Ethiopia, Malawi, Kenya and Zambia)
require that a local PI be associated with any research
on country samples or data taking place outside the
country while in Nigeria the PI must be affiliated to a
registered institution in Nigeria capable of doing the
proposed study. Malawi and Zambia require that all
foreign-based researchers be affiliated to one of the local
research institutions while in Zimbabwe, foreign re-
searchers are required to obtain registration from the
Research Council of Zimbabwe.
Nine countries (Botswana, Cameroon, Ethiopia, Ghana,
Kenya, Rwanda, Uganda, Zambia and Zimbabwe) specifically
mention and endorse international collaboration—guidelines
for the other countries are silent on this topic. Guide-
lines for Botswana, Kenya and Uganda stipulate that
export of samples is only allowed when there is no
capacity in the country to conduct the same analy-
ses—a requirement that appears to be quite strictly
enforced in at least Botswana. These provisions are
accompanied by a strong recommendation (Uganda)
or requirement (Botswana and Kenya) that local cap-
acity is built or strengthened where the export of
samples is concerned. These nine countries require
that international collaborative research be responsive
to the health needs of the population. In Botswana,
Ethiopia and Kenya, international collaboration needs
to lead to capacity building. Malawi and Lesotho do
not offer guidance for international collaboration
whilst they do offer guidance for the export of sam-
ples—which implies international collaboration. In
Ethiopia and Kenya, a local co-investigator needs to
be included in all future studies making use of stored
or exported samples. In Tanzania, if there is local
technology for analysis in country, the researcher
must explain why the samples are being sent out of
the country. They must note whether or not a local
Tanzanian is involved in analysis. In Malawi, export
of samples is discouraged.
Data and sample sharing
Only guidelines from Cameroon, Ethiopia and Tanzania
specifically mention data sharing. Cameroon and
Tanzania require a Data Sharing Agreement to be sub-
mitted as part of the ethics review application. Ethiopian
guidelines stipulate that an Ethiopian ethics committee
needs to review all secondary studies, also if samples are
stored abroad.
Ownership of samples
Ethics documents from seven countries refer to own-
ership of samples collected as part of research. In
Zambia, the Minister of Health, in consultation with
the National Health Research Authority, is responsible
for making a decision on ownership of biological ma-
terials, including derivatives and modifications, col-
lected as part of research. In Malawi, samples remain
the property of the Ministry of Health. In Botswana,
Ghana, Ethiopia, Rwanda and Uganda the institution
that collected the samples has custodianship of the
samples and holds the samples in trust on behalf of
the research participants and the government.
Cameroon and Nigeria are not prescriptive about sam-
ple ownership, but guidance indicates that decisions on
ownership of samples have to be agreed by local
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investigators and their collaborators before the start of
the research and a copy of the agreement needs to be
submitted to the ethics review committee.
Return of genetic results
Documents from seven countries (Botswana, Cameroon,
Ethiopia, Rwanda, Malawi, Sudan and Uganda) specific-
ally refer to return of genetic results. One important
concern across these countries seems to be the impact
of genetic research on family members, and whether or
not these should also be included in feedback. For in-
stance, Ethiopian guidelines stipulate that individual re-
search results should not be given to family members or
third parties without written permission from the sub-
ject and approval by the National Health Research Ethics
Council. In Malawi, return of genetic results would be
determined by the investigator based on the sensitivity
and specificity of the test and participants would have to
consent to disclosure of results. If genetic study results
are shared then this has to be done by a genetic
counsellor. In Botswana and Cameroon, when return of
results is planned, participants should be asked to decide
whether or not they want to receive individual genetic
test results. In Cameroon, the feedback of genetic study
results will also require genetic counselling and partici-
pants must be informed whether the test is available out-
side the research context and who would have access to
the study results. In Rwanda results of genetic test are
not to be divulged to third parties unless properly autho-
rized. However, the authority required for giving permis-
sion is not indicated. In Uganda, any result that are of
clinical relevance, including incidental findings, must be
fed back to study participants. In Sudan, participants
need to be informed, during the consent process, of the
policy in place for feeding back genetic test results and
the precautions in place to prevent unauthorized disclos-
ure of a participants’ genetic study results.
Discussion
In this review, we examined the existing ethics regu-
latory framework for genomic research and biobank-
ing in 22 African countries. Guidance for genomic
research and biobanking takes place at three levels:
considerations of genomics and biobanking are either
completely absent from the regulatory environment,
incorporated within the broader ethics framework for
health research, or published as separate texts. The
absence of regulation for genomic research in Africa
is not peculiar to genomic research but biomedical
research as a whole, [29] note that most countries are
still developing standard operating procedures for
their research ethics committees and some countries
do not have existing guidelines for health research
despite ongoing research in these countries. This may
explain why we were only effective in sourcing guid-
ance documents from 22 countries out of the 54 that
make up the continent—there may not have been any
in the other countries.
The study shows that just three countries have specific
guidelines for genomic or biobanking research. Overall,
many of documents we analysed seem to have been de-
veloped in response to clinical trials, epidemiological re-
search or more broadly to health research—and the
principles put forth are then taken to apply to genomic
research and biobanking in the same way. This extension
is problematic because these ethical principles do not ac-
commodate changing scientific practices which involve
the sharing and secondary use of resources globally, in-
cluding associated changes in consent.
Where specific ethics guidelines are absent, re-
searchers and ethics committees are left to make their
own decisions, without a framework for their delibera-
tions and decisions. The risk is that fears and misunder-
standing could then guide decision-making—which
would hardly be conducive to thorough ethical reflec-
tion. We found that in those countries where guidelines
are very specific, they run the risk of becoming quickly
outdated in the context of rapidly evolving research.
This is the case for Malawi and Zambia, for instance,
where very specific provisions for genomic research and
biobanking appear to have started to obstruct genomic
research in those countries.
Discussions with ethics committees in the context of
H3Africa research (de Vries et al, [14, 15, 30] have sug-
gested that many ethics committee members struggle
with the notion of ‘broad consent’—the type of consent
required to allow broad re-use of samples and data for
secondary research. It is therefore surprising that our
analysis revealed that broad consent is (apparently)
allowed in all but three countries (Zambia, Malawi and
Tanzania). In Zambia, the use of broad consent is illegal
according to the Health Act 2013; in Malawi and
Tanzania, the language used in the ethics documentation
suggests that broad consent is not allowed. In all the
other countries we examined, guidelines are either silent
on the type of consent that can be used for genomic re-
search, they allow consent for ‘future unspecified use’, or
specifically endorse broad consent as a valid consent
model in health research. This trend is encouraging as it
means that there is no a priori reason to be concerned
about the possibility that broad consent can be used in
the majority of African countries [7].
One defining characteristic of genomics and biobank-
ing studies is the sharing of resources, including samples
and data, for secondary use globally. An essential and
critical component of ensuring that secondary use is
aligned with ethical principles and best practice is in
regulating secondary use through governance. It is
de Vries et al. BMC Medical Ethics  (2017) 18:8 Page 7 of 9
therefore problematic that data and sample sharing are
most sparingly covered in the guidelines with only
Cameroon, Ethiopia and Tanzania incorporating sections
that focus on data sand sample sharing. Whilst ten
countries have specific guidance for export of samples,
and nine countries specifically mention and allow inter-
national collaboration, beyond MTAs none of the coun-
tries require a description of the governance of
secondary research including sample and data sharing
policies.
Guidelines for only three countries were specific to
genetic, genomic or biobanking research. Although
guidelines in many other countries describe regula-
tions for export of samples for instance, we suspect
that in most cases these regulations pertain to the
sharing of samples between collaborators, for specific
projects. The sharing of samples in the context of
biobanking research—including the export of samples
for biobanking elsewhere, or the export of cell line-
s—may not have been intended or imagined when
guidelines were drafted. This complicates the applic-
ability of existing guidelines to such research. Of the
countries that specifically mention export of samples,
many require national-level approval in addition to
‘local’ ethics review; a justification for why the work
cannot happen in-country; a document regulating the
exchange (export permit, MTA) and sometimes in-
volvement of a national researcher in the overseas
work. Interestingly, the guidelines are completely si-
lent on ethical issues or responsibilities associated
with the import of samples into African countries.
A limitation of this paper is that it focuses solely
on ethics regulatory documents and not on ethics
review practices. These are obviously different and
the difference is important: for instance, although
the Tanzanian and Malawian documents we perused
suggest that broad consent is not allowed, we know
that ethics committees in these countries have in the
past approved studies that used a broad consent
model. Similarly, although the use of broad consent
is apparently allowed in most African countries,
within H3Africa there have been several instances of
ethics review committees questioning whether broad
consent is ethical. It is important therefore to go be-
yond document analysis to investigate actual review
practices and what ethics committee members be-
lieve is written in the regulatory documents. In a
similar vein, our focus on mostly national docu-
ments, with few institutional or committee policies
(Ghana, South Africa and Tanzania), also means that
we might have missed important nuances in the way
in which national policies are implemented or inter-
preted locally. An example would be the absence of
a national requirement for Material Transfer
Agreements in South Africa—most research institu-
tions in this country would require these in any
case, even if the national regulator does not.
Conclusion
Overall, in the rapidly changing landscape of science—e-
pitomised in the fields of genomic research and bioban-
king—ethics guidelines need to be broad and flexible
enough to accommodate changes, whilst also offering
guidance on the principles that should be applied to fos-
ter ethically sound health research. Key principles that
ought to be incorporated into African guidance for gen-
omic research and biobanking relate to promoting Afri-
can leadership and ownership of genomics and
biobanking science and capacity strengthening as an es-
sential feature of international collaboration. In terms of
specific guidance supporting ethics committee decision-
making, we think that what is required are guidelines
that address issues relating to sample and data sharing
and the requirements of governance frameworks sup-
porting these. What is also required is a clear statement,
by African governments, national health ethics councils
or other authorities charged with developing the ethical
frameworks for research, about the appropriateness of
using broad consent in the context of African genomics
and biobanking research.
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